Brändle J, Lageder H, Irsigler K
Wien Klin Wochenschr. 1977 Mar 4;89(5):164-7.
Midodrine, which is used in the treatment of hypotensive circulatory distrubances was investigated with respect to possible effects on carbohydrate and fat metabolism in 5 healthy subjects and 7 patients with disturbed glocuse tolerance. An i.v. glucose tolerance test was carried out on both groups and was repeated a few days subsequently with simultaneous administration of midodrine (5mg i.v.). Midodrine had no significant effect on glucose tolerance in either group, nor was there any significant effect of midodrine on FFA, serum insulin, triglyceride or cholesterol levels. 15 diabetic patients controlled by different therapeutic regimens (5 by diet only, 5 by oral preparations and 5 by insulin treatment) were given 3x5mg midodrine orally over a 5-day period and the effects on diabetic control and metabolic parameters compared with a 5-day pretreatment period without midodrine. Midodrine did not cause any change in the quality of diabetic control nor any significant alteration in serum lipid or uric acid levels.
对用于治疗低血压性循环障碍的米多君,在5名健康受试者和7名葡萄糖耐量受损患者中研究了其对碳水化合物和脂肪代谢的可能影响。对两组均进行了静脉葡萄糖耐量试验,并在随后几天重复进行,同时静脉注射米多君(5毫克)。米多君对两组的葡萄糖耐量均无显著影响,对游离脂肪酸、血清胰岛素、甘油三酯或胆固醇水平也无显著影响。15名通过不同治疗方案控制的糖尿病患者(5名仅通过饮食控制,5名通过口服制剂控制,5名通过胰岛素治疗)在5天内口服3次,每次5毫克米多君,并将其对糖尿病控制和代谢参数的影响与无米多君的5天预处理期进行比较。米多君未引起糖尿病控制质量的任何变化,也未引起血清脂质或尿酸水平的任何显著改变。